APP as a common denominator for Alzheimer's disease and osteoporosis
APP 是阿尔茨海默病和骨质疏松症的共同点
基本信息
- 批准号:9607371
- 负责人:
- 金额:$ 28.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-15 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Osteoporosis, a common skeletal degenerative disorder, is characterized by decrease of bone- mass and micro-architectural deterioration of bone tissue. Alzheimer's disease (AD) is a most common neurodegenerative disorder with cognitive dementia. Intriguingly, AD patients frequently have lower bone mineral density and higher rate of hip fracture, compared with the same age normal population. Several newly identified AD risk genes/loci encode proteins critical for osteoclastic activation and/or bone-mass homeostasis. Increasing evidence from clinical and genetic studies thus supports a degree of co-morbidity of both disorders. However, very few studies are available to address their relationship. The goal of this proposal is to determine if and how the Swedish mutant amyloid precursor protein (APPswe) acts as a common denominator for AD and osteoporosis/osteopenia. APP is a ubiquitously expressed transmembrane protein. Its cleavage product, A, is believed to be a major culprit for both early- and late-onset AD. We thus speculate that APP/A may contribute to the AD-associated skeletal deficits. By use of Tg2576 mice, a well-characterized AD animal model that ubiquitously expresses APPswe under the control of prion promoter, we observed age-dependent osteoporotic bone deficits in this animal model. By use of newly generated conditional/cell type specific APPswe transgenic mouse models, we found that APPswe plays important roles in regulating osteoblast (OB)-mediated bone formation and osteoclast (OC)-mediated bone resorption. However, the underlying mechanisms are unclear. In this proposal, we will address this issue. It is our hope that the results from this research may not only provide a potential link between AD and osteoporosis/osteopenia, but also identify unrecognized functions of APP and reveal new pathological mechanisms underlying both disorders.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WEN-CHENG XIONG其他文献
WEN-CHENG XIONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WEN-CHENG XIONG', 18)}}的其他基金
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development
瑞典骨骼肌突变体 APP 在阿尔茨海默病发展中的作用
- 批准号:
10254624 - 财政年份:2021
- 资助金额:
$ 28.61万 - 项目类别:
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development
瑞典骨骼肌突变体 APP 在阿尔茨海默病发展中的作用
- 批准号:
10513298 - 财政年份:2021
- 资助金额:
$ 28.61万 - 项目类别:
Retromer deficiency and Alzheimer's disease pathology
逆转录酶缺乏与阿尔茨海默病病理学
- 批准号:
9605932 - 财政年份:2017
- 资助金额:
$ 28.61万 - 项目类别:
APP as a common denominator for Alzheimer's disease and osteoporosis
APP 是阿尔茨海默病和骨质疏松症的共同点
- 批准号:
9903240 - 财政年份:2016
- 资助金额:
$ 28.61万 - 项目类别:
APP as a common denominator for Alzheimer's disease and osteoporosis
APP 是阿尔茨海默病和骨质疏松症的共同点
- 批准号:
9323223 - 财政年份:2016
- 资助金额:
$ 28.61万 - 项目类别:
Retromer deficiency and Alzheimer's disease pathology
逆转录酶缺乏与阿尔茨海默病病理学
- 批准号:
9059562 - 财政年份:2014
- 资助金额:
$ 28.61万 - 项目类别:
Retromer deficiency and Alzheimer's disease pathology
逆转录酶缺乏与阿尔茨海默病病理学
- 批准号:
9486649 - 财政年份:2014
- 资助金额:
$ 28.61万 - 项目类别:
Retromer deficiency and Alzheimer's disease pathology
逆转录酶缺乏与阿尔茨海默病病理学
- 批准号:
8842912 - 财政年份:2014
- 资助金额:
$ 28.61万 - 项目类别:
Retromer deficiency and Alzheimer's disease pathology
逆转录酶缺乏与阿尔茨海默病病理学
- 批准号:
8708256 - 财政年份:2014
- 资助金额:
$ 28.61万 - 项目类别:
相似国自然基金
青藏高原高寒植物酚类物质分配格局的研究:基于“Common garden”实验
- 批准号:31200306
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
精神分裂症遗传易感性及发病机理研究
- 批准号:81130022
- 批准年份:2011
- 资助金额:270.0 万元
- 项目类别:重点项目
基于全基因组关联研究数据二次分析的肿瘤候选基因变异研究
- 批准号:81101545
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
陆面过程模拟中参数的不确定性和随机误差传播研究
- 批准号:40775041
- 批准年份:2007
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
持続可能性の実現へ向けた幼児期の日本型Common Worlds Pedagogyの研究
为实现可持续发展而进行的日式幼儿共同世界教育学研究
- 批准号:
24K05787 - 财政年份:2024
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
- 批准号:
MR/Y013891/1 - 财政年份:2024
- 资助金额:
$ 28.61万 - 项目类别:
Research Grant
企業統治における機関投資家のあり方――共通株主(Common Ownership)の視点
机构投资者在公司治理中的作用——共同所有权视角
- 批准号:
24K16271 - 财政年份:2024
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
An Eye-Tracking Study: Exploring Integrated Reading Tasks in the New Format of the English Common Test for Japanese University Admissions
眼动追踪研究:探索日本大学入学英语通用考试新形式中的综合阅读任务
- 批准号:
24K04032 - 财政年份:2024
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidating the nature of the symbiosis between reef-building corals and common Endozoicomonas bacteria
阐明造礁珊瑚与常见内生单胞菌之间共生的本质
- 批准号:
2342561 - 财政年份:2024
- 资助金额:
$ 28.61万 - 项目类别:
Continuing Grant
Pathfinder Parks: Implementing a common framework to track & accelerate progress towards Net Zero in the South Downs National Park using the OnePlanet Platform.
Pathfinder Parks:实施通用框架来跟踪
- 批准号:
10093123 - 财政年份:2024
- 资助金额:
$ 28.61万 - 项目类别:
Demonstrator
SCC-CIVIC-FA Track B: Piloting a Decarbonization-Ready Common Home Assessment
SCC-CIVIC-FA 轨道 B:试点脱碳就绪的共同家庭评估
- 批准号:
2321865 - 财政年份:2024
- 资助金额:
$ 28.61万 - 项目类别:
Continuing Grant
Pioneer Parks: Modelling a common framework to track and accelerate progress towards Net Zero in National Parks using the One Planet Platform
先锋公园:使用 One Planet 平台建立一个通用框架来跟踪和加速国家公园实现净零排放的进展
- 批准号:
10061261 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Feasibility Studies
Accelerating drug discovery via ML-guided iterative design and optimization
通过机器学习引导的迭代设计和优化加速药物发现
- 批准号:
10552325 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:














{{item.name}}会员




